BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Riedl SJ, Pasquale EB. Targeting the Eph System with Peptides and Peptide Conjugates. Curr Drug Targets 2015;16:1031-47. [PMID: 26212263 DOI: 10.2174/1389450116666150727115934] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Zapata-Mercado E, Biener G, McKenzie DM, Wimley WC, Pasquale EB, Raicu V, Hristova K. The efficacy of receptor tyrosine kinase EphA2 autophosphorylation increases with EphA2 oligomer size. J Biol Chem 2022;:102370. [PMID: 35970390 DOI: 10.1016/j.jbc.2022.102370] [Reference Citation Analysis]
2 Guidetti L, Castelli R, Scalvini L, Ferlenghi F, Corrado M, Giorgio C, Tognolini M, Lodola A. Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids. Pharmaceuticals 2022;15:137. [DOI: 10.3390/ph15020137] [Reference Citation Analysis]
3 Ganguly D, Thomas JA, Ali A, Kumar R. Mechanistic and therapeutic implications of EphA-4 receptor tyrosine kinase in the pathogenesis of Alzheimer's disease. Eur J Neurosci 2022. [PMID: 34989046 DOI: 10.1111/ejn.15591] [Reference Citation Analysis]
4 Nilvebrant J, Ereño-Orbea J, Gorelik M, Julian MC, Tessier PM, Julien JP, Sidhu SS. Systematic Engineering of Optimized Autonomous Heavy-Chain Variable Domains. J Mol Biol 2021;433:167241. [PMID: 34508727 DOI: 10.1016/j.jmb.2021.167241] [Reference Citation Analysis]
5 Goudsmit C, da Veiga Leprevost F, Basrur V, Peters L, Nesvizhskii A, Walline H. Differences in Extracellular Vesicle Protein Cargo Are Dependent on Head and Neck Squamous Cell Carcinoma Cell of Origin and Human Papillomavirus Status. Cancers (Basel) 2021;13:3714. [PMID: 34359613 DOI: 10.3390/cancers13153714] [Reference Citation Analysis]
6 Ahmed MS, Wang P, Nguyen NUN, Nakada Y, Menendez-Montes I, Ismail M, Bachoo R, Henkemeyer M, Sadek HA, Kandil ES. Identification of tetracycline combinations as EphB1 tyrosine kinase inhibitors for treatment of neuropathic pain. Proc Natl Acad Sci U S A 2021;118:e2016265118. [PMID: 33627480 DOI: 10.1073/pnas.2016265118] [Reference Citation Analysis]
7 Hanley T, Yin R, Mac J, Tan W, Anvari B. Functionalized erythrocyte-derived optical nanoparticles to target ephrin-B2 ligands. J Biomed Opt 2019;24:1-9. [PMID: 31429216 DOI: 10.1117/1.JBO.24.8.085002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
8 de Muijnck C, van Gorkom Y, van Duijvenvoorde M, Eghtesadi M, Dekker-Ensink G, Bhairosingh SS, Affinito A, Kuppen PJK, Vahrmeijer AL, Sier CFM. Evaluation of EphB4 as Target for Image-Guided Surgery of Breast Cancer. Pharmaceuticals (Basel) 2020;13:E172. [PMID: 32751634 DOI: 10.3390/ph13080172] [Reference Citation Analysis]
9 Baudet S, Bécret J, Nicol X. Approaches to Manipulate Ephrin-A:EphA Forward Signaling Pathway. Pharmaceuticals (Basel) 2020;13:E140. [PMID: 32629797 DOI: 10.3390/ph13070140] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
10 Hughes RM, Virag JAI. Harnessing the Power of Eph/ephrin Biosemiotics for Theranostic Applications. Pharmaceuticals (Basel) 2020;13:E112. [PMID: 32492868 DOI: 10.3390/ph13060112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
11 Tiruppathi C, Regmi SC, Wang DM, Mo GCH, Toth PT, Vogel SM, Stan RV, Henkemeyer M, Minshall RD, Rehman J, Malik AB. EphB1 interaction with caveolin-1 in endothelial cells modulates caveolae biogenesis. Mol Biol Cell 2020;31:1167-82. [PMID: 32238105 DOI: 10.1091/mbc.E19-12-0713] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Moyano-Galceran L, Pietilä EA, Turunen SP, Corvigno S, Hjerpe E, Bulanova D, Joneborg U, Alkasalias T, Miki Y, Yashiro M, Chernenko A, Jukonen J, Singh M, Dahlstrand H, Carlson JW, Lehti K. Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer. EMBO Mol Med 2020;12:e11177. [PMID: 32115889 DOI: 10.15252/emmm.201911177] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
13 Incerti M, Russo S, Corrado M, Giorgio C, Ballabeni V, Chiodelli P, Rusnati M, Scalvini L, Callegari D, Castelli R, Vacondio F, Ferlenghi F, Tognolini M, Lodola A. Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties. Eur J Med Chem 2020;189:112083. [PMID: 32000051 DOI: 10.1016/j.ejmech.2020.112083] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Pereira-Silva M, Alvarez-Lorenzo C, Concheiro A, Santos AC, Veiga F, Figueiras A. Nanomedicine in osteosarcoma therapy: Micelleplexes for delivery of nucleic acids and drugs toward osteosarcoma-targeted therapies. Eur J Pharm Biopharm 2020;148:88-106. [PMID: 31958514 DOI: 10.1016/j.ejpb.2019.10.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
15 Xiong C, Wen Y, Zhao J, Yin D, Xu L, Chelariu-Raicu A, Yao C, Leng X, Liu J, Chaudhari RR, Zhang S, Sood AK, Li C. Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions. Sci Rep 2020;10:520. [PMID: 31949258 DOI: 10.1038/s41598-020-57477-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
16 Kowalski EA, Chen J, Hazy A, Fritsch LE, Gudenschwager-Basso EK, Chen M, Wang X, Qian Y, Zhou M, Byerly M, Pickrell AM, Matson JB, Allen IC, Theus MH. Peripheral loss of EphA4 ameliorates TBI-induced neuroinflammation and tissue damage. J Neuroinflammation 2019;16:210. [PMID: 31711546 DOI: 10.1186/s12974-019-1605-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
17 Gomez-Soler M, Petersen Gehring M, Lechtenberg BC, Zapata-Mercado E, Hristova K, Pasquale EB. Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling. J Biol Chem 2019;294:8791-805. [PMID: 31015204 DOI: 10.1074/jbc.RA119.008213] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
18 Mercurio FA, Di Natale C, Pirone L, Marasco D, Calce E, Vincenzi M, Pedone EM, De Luca S, Leone M. Design and analysis of EphA2-SAM peptide ligands: A multi-disciplinary screening approach. Bioorganic Chemistry 2019;84:434-43. [DOI: 10.1016/j.bioorg.2018.12.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
19 Ieguchi K, Maru Y. Roles of EphA1/A2 and ephrin-A1 in cancer. Cancer Sci 2019;110:841-8. [PMID: 30657619 DOI: 10.1111/cas.13942] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
20 Saha N, Robev D, Mason EO, Himanen JP, Nikolov DB. Therapeutic potential of targeting the Eph/ephrin signaling complex. Int J Biochem Cell Biol 2018;105:123-33. [PMID: 30343150 DOI: 10.1016/j.biocel.2018.10.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
21 Baindara P, Korpole S, Grover V. Bacteriocins: perspective for the development of novel anticancer drugs. Appl Microbiol Biotechnol 2018;102:10393-408. [PMID: 30338356 DOI: 10.1007/s00253-018-9420-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 10.3] [Reference Citation Analysis]
22 Kalmykova SD, Arapidi GP, Urban AS, Osetrova MS, Gordeeva VD, Ivanov VT, Govorun VM. In Silico Analysis of Peptide Potential Biological Functions. Russ J Bioorg Chem 2018;44:367-85. [DOI: 10.1134/s106816201804009x] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
23 Chatzisideri T, Leonidis G, Sarli V. Cancer-targeted delivery systems based on peptides. Future Med Chem 2018;10:2201-26. [PMID: 30043641 DOI: 10.4155/fmc-2018-0174] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
24 Singh DR, Kanvinde P, King C, Pasquale EB, Hristova K. The EphA2 receptor is activated through induction of distinct, ligand-dependent oligomeric structures. Commun Biol 2018;1:15. [PMID: 30271902 DOI: 10.1038/s42003-018-0017-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 10.0] [Reference Citation Analysis]
25 Salgia R, Kulkarni P, Gill PS. EphB4: A promising target for upper aerodigestive malignancies. Biochim Biophys Acta Rev Cancer 2018;1869:128-37. [PMID: 29369779 DOI: 10.1016/j.bbcan.2018.01.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
26 Hu W, Xie Q, Xiang H. Improved scFv Anti-LOX-1 Binding Activity by Fusion with LOX-1-Binding Peptides. Biomed Res Int 2017;2017:8946935. [PMID: 29094051 DOI: 10.1155/2017/8946935] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
27 Lodola A, Giorgio C, Incerti M, Zanotti I, Tognolini M. Targeting Eph/ephrin system in cancer therapy. Eur J Med Chem 2017;142:152-62. [PMID: 28780190 DOI: 10.1016/j.ejmech.2017.07.029] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 8.4] [Reference Citation Analysis]
28 Lechtenberg BC, Mace PD, Sessions EH, Williamson R, Stalder R, Wallez Y, Roth GP, Riedl SJ, Pasquale EB. Structure-Guided Strategy for the Development of Potent Bivalent ERK Inhibitors. ACS Med Chem Lett 2017;8:726-31. [PMID: 28740606 DOI: 10.1021/acsmedchemlett.7b00127] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
29 Stammes MA, Prevoo HA, Ter Horst MC, Groot SA, Van de Velde CJ, Chan AB, de Geus-Oei LF, Kuppen PJ, Vahrmeijer AL, Pasquale EB, Sier CF. Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery. Int J Mol Sci 2017;18:E307. [PMID: 28165374 DOI: 10.3390/ijms18020307] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
30 Incerti M, Russo S, Callegari D, Pala D, Giorgio C, Zanotti I, Barocelli E, Vicini P, Vacondio F, Rivara S, Castelli R, Tognolini M, Lodola A. Metadynamics for Perspective Drug Design: Computationally Driven Synthesis of New Protein-Protein Interaction Inhibitors Targeting the EphA2 Receptor. J Med Chem 2017;60:787-96. [PMID: 28005388 DOI: 10.1021/acs.jmedchem.6b01642] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
31 Olson EJ, Lechtenberg BC, Zhao C, Rubio de la Torre E, Lamberto I, Riedl SJ, Dawson PE, Pasquale EB. Modifications of a Nanomolar Cyclic Peptide Antagonist for the EphA4 Receptor To Achieve High Plasma Stability. ACS Med Chem Lett 2016;7:841-6. [PMID: 27660688 DOI: 10.1021/acsmedchemlett.6b00132] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
32 Zarei O, Benvenuti S, Ustun-Alkan F, Hamzeh-Mivehroud M, Dastmalchi S. Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery. J Cancer Res Clin Oncol. 2016;142:2429-2446. [PMID: 27503093 DOI: 10.1007/s00432-016-2214-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
33 Barquilla A, Lamberto I, Noberini R, Heynen-Genel S, Brill LM, Pasquale EB. Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation. Mol Biol Cell 2016;27:2757-70. [PMID: 27385333 DOI: 10.1091/mbc.E16-01-0048] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
34 Singh DR, Pasquale EB, Hristova K. A small peptide promotes EphA2 kinase-dependent signaling by stabilizing EphA2 dimers. Biochim Biophys Acta 2016;1860:1922-8. [PMID: 27281300 DOI: 10.1016/j.bbagen.2016.06.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]